Try
Merck & Co., Inc.
MRKUnited States
85 filed reports · 674 financial concepts · 40 earnings calls · 16 media appearances
Filed reports
85 reports · Jun 2016 to Jun 2026Each report counts once it has at least one extracted financial fact. Also extracted from these reports: 313 guidance figures, 259 commentary passages.
| Report type | Reports | Facts | Periods |
|---|---|---|---|
| Quarterly · 10-QSEC EDGAR | 38 | 9,670 | Jun 2016 to Jun 2026 |
| Current · 8-KSEC EDGAR | 34 | 349 | Mar 2018 to Jun 2026 |
| Annual · 10-KSEC EDGAR | 12 | 9,501 | Dec 2016 to Dec 2025 |
| Annual · 10-K/ASEC EDGAR | 1 | 1 | Dec 2023 |
Documents
| Period | Type | Period end | Published | Facts | Source |
|---|---|---|---|---|---|
| FY2026 Q2 | 10-Q | Jun 30, 2026 | Aug 7, 2026 | 592 | Open |
| FY2026 Q2 | 10-Q | Jun 30, 2026 | Aug 7, 2026 | 15 | Open |
| FY2026 Q2 | 8-K | Jun 30, 2026 | Aug 4, 2026 | 8 | Open |
| FY2026 Q1 | 10-Q | Mar 31, 2026 | May 4, 2026 | 438 | Open |
| FY2026 Q1 | 10-Q | Mar 31, 2026 | May 4, 2026 | 8 | Open |
| FY2026 Q1 | 8-K | Mar 31, 2026 | Apr 30, 2026 | 8 | Open |
| FY2025 | 10-K | Dec 31, 2025 | Feb 24, 2026 | 21 | Open |
| FY2025 | 10-K | Dec 31, 2025 | Feb 24, 2026 | 1,675 | Open |
| FY2025 Q4 | 8-K | Dec 31, 2025 | Feb 3, 2026 | 4 | Open |
| FY2025 Q3 | 10-Q | Sep 30, 2025 | Nov 5, 2025 | 466 | Open |
| FY2025 Q3 | 10-Q | Sep 30, 2025 | Nov 5, 2025 | 15 | Open |
| FY2025 Q3 | 8-K | Sep 30, 2025 | Oct 30, 2025 | 8 | Open |
Financial data
674 concepts · 19,521 factsEach concept is one reported line item or metric. The count is how many values of it are held, across the periods shown.
Financial620 concepts · 11,704 facts · Oct 2014 to Jul 2026
- Accumulated other comprehensive income loss net of tax58 · Dec 2014 to Jun 2026
- Cash and cash equivalents at carrying value58 · Dec 2014 to Jun 2026
- Stockholders equity including portion attributable to noncontrolling interest58 · Dec 2014 to Jun 2026
- Comprehensive income net of tax57 · Dec 2014 to Jun 2026
- Foreign currency transaction gain loss before tax57 · Dec 2014 to Jun 2026
- Income tax expense benefit57 · Dec 2014 to Jun 2026
- Investment income interest57 · Dec 2014 to Jun 2026
- Net income loss57 · Dec 2014 to Jun 2026
- Net income loss attributable to noncontrolling interest57 · Dec 2014 to Jun 2026
- Other, net57 · Dec 2014 to Jun 2026
- Other nonoperating income expense57 · Dec 2014 to Jun 2026
- Research and development expense57 · Dec 2014 to Jun 2026
- Restructuring and related cost incurred cost57 · Dec 2014 to Jun 2026
- Restructuring charges57 · Dec 2014 to Jun 2026
- Revenue57 · Dec 2014 to Jun 2026
- Selling general and administrative expense57 · Dec 2014 to Jun 2026
- Share based compensation57 · Dec 2014 to Jun 2026
- Total Costs, Expenses and Other57 · Dec 2014 to Jun 2026
- Business combination contingent consideration liability56 · Dec 2014 to Dec 2025
- Deferred income tax expense benefit56 · Dec 2014 to Jun 2026
- Dividends common stock cash56 · Dec 2014 to Jun 2026
- Other comprehensive income loss net of tax56 · Dec 2014 to Jun 2026
- Other noncash income expense56 · Dec 2014 to Jun 2026
- Payments for proceeds from other investing activities56 · Dec 2014 to Jun 2026
Segment19 concepts · 6,654 facts · Dec 2014 to Jun 2026
- Revenue6,210 · Dec 2014 to Jun 2026
- Income loss from continuing operations before income taxes extraordinary items noncontrolling interest114 · Dec 2014 to Jun 2026
- Income loss from equity method investments51 · Dec 2014 to Jun 2026
- Depreciation30 · Dec 2021 to Jun 2026
- Cost of goods and services sold (US GAAP)28 · Dec 2022 to Jun 2026
- Other nonoperating income expense28 · Dec 2022 to Jun 2026
- Research and development expense28 · Dec 2022 to Jun 2026
- Selling general and administrative expense28 · Dec 2022 to Jun 2026
- Depreciation depletion and amortization25 · Dec 2014 to Dec 2022
- Goodwill24 · Dec 2015 to Dec 2025
- Goodwill acquired during period21 · Dec 2015 to Dec 2024
- Goodwill impairment loss21 · Dec 2015 to Dec 2019
- Goodwill other increase decrease21 · Dec 2015 to Dec 2022
- Revenue from collaborative arrangement excluding revenue from contract with customer7 · Dec 2021 to Dec 2023
- Goodwill translation and purchase accounting adjustments6 · Dec 2022 to Dec 2024
- Goodwill written off related to sale of business unit5 · Dec 2015 to Dec 2020
- Goodwill foreign currency translation gain loss4 · Dec 2024 to Dec 2025
- Goodwill purchase accounting adjustments2 · Dec 2025
- Income taxes paid1 · Dec 2014
Geography7 concepts · 649 facts · Dec 2014 to Jun 2026
- Revenue514 · Dec 2014 to Jun 2026
- Property, Plant & Equipment, Net122 · Dec 2015 to Jun 2026
- Defined benefit plan assumptions used calculating net periodic benefit cost discount rate3 · Dec 2014 to Dec 2016
- Defined benefit plan assumptions used calculating net periodic benefit cost expected long term return on assets3 · Dec 2014 to Dec 2016
- Defined benefit plan assumptions used calculating net periodic benefit cost rate of compensation increase3 · Dec 2014 to Dec 2016
- Foreign currency transaction gain loss realized3 · Jun 2015 to Dec 2015
- United States1 · Dec 2016
Guidance14 concepts · 355 facts · May 2018 to Aug 2026
- Effective Tax Rate Guidance70 · May 2018 to Aug 2026
- EPS (Diluted) Guidance68 · May 2018 to Aug 2026
- Revenue Guidance68 · May 2018 to Aug 2026
- EPS (Diluted) Guidance (Adjusted (non-GAAP))42 · May 2018 to Apr 2023
- Effective Tax Rate Guidance (Adjusted (non-GAAP))40 · May 2018 to Feb 2023
- Gross Margin Guidance28 · Feb 2022 to Aug 2026
- Revenue Guidance (Adjusted (non-GAAP))14 · Jul 2018 to Oct 2021
- Revenue Growth Guidance10 · Jul 2021 to Oct 2022
- Gross Margin Guidance (Adjusted (non-GAAP))6 · Feb 2022 to Apr 2023
- Capital Expenditures Guidance2 · Oct 2018
- Revenue Growth Guidance (At current exchange rates)2 · Apr 2021
- Revenue Growth Guidance (Excluding LAGEVRIO)2 · Oct 2022
- Revenue Guidance (continuing operations)2 · Apr 2021
- Operating Margin Guidance1 · Apr 2021
Product14 concepts · 159 facts · Dec 2014 to Dec 2025
- Intangible Assets (excluding Goodwill)60 · Dec 2016 to Dec 2025
- Impairment of intangible assets indefinitelived excluding goodwill34 · Jun 2015 to Dec 2021
- Impairment of intangible assets finitelived24 · Dec 2014 to Dec 2020
- Adjustment for amortization14 · Dec 2020 to Sep 2023
- Business combination contingent consideration arrangements change in amount of contingent consideration liability16 · Dec 2016 to Dec 2025
- COVID-196 · Dec 2020 to Dec 2021
- Loss contingency claims settled number5 · Dec 2023 to Mar 2025
- Fair value measurement with unobservable inputs reconciliation recurring basis liability settlements4 · Sep 2018 to Dec 2025
- Gain loss related to litigation settlement1 · Dec 2020
- Inventory1 · Jul 2020
- Inventory write down1 · Dec 2020
- Proceeds from sales of intangible assets classified as investing activities1 · Dec 2014
- Production related impairments or charges1 · Dec 2020
- Research and development expense1 · Dec 2020
Segments
7,462 factsFigures broken down by business line, region, product or another axis the company reports on.
Statement business segments8 members · 6,654 facts
- Pharmaceuticalsegment5,856 · Dec 2014 to Jun 2026
- Animal Healthsegment599 · Dec 2016 to Jun 2026
- All Other Segments165 · Dec 2014 to Dec 2022
- Pharmaceuticalsegment12 · Dec 2015 to Dec 2025
- Animal healthsegment9 · Dec 2017 to Dec 2025
- Healthcare Services8 · Dec 2018 to Dec 2019
- All other segments4 · Dec 2015 to Dec 2019
- Consumer Care1 · Dec 2014
Statement geographicalsrt:StatementGeographicalAxis15 members · 521 facts
- Non Us94 · Dec 2016 to Jun 2026
- US94 · Dec 2016 to Jun 2026
- EMEA47 · Dec 2016 to Jun 2026
- Latin America47 · Dec 2016 to Jun 2026
- Other Countries47 · Dec 2016 to Jun 2026
- JP46 · Dec 2016 to Jun 2026
- Asia Pacific45 · Dec 2016 to Jun 2026
- CN43 · Dec 2016 to Jun 2026
- Cn16 · Dec 2017 to Jun 2026
- Jp7 · Dec 2024 to Jun 2026
- Us7 · Dec 2024 to Jun 2026
- Other countries7 · Dec 2024 to Jun 2026
- Asia pacific7 · Dec 2024 to Jun 2026
- Latin america7 · Dec 2024 to Jun 2026
- Emea7 · Dec 2024 to Jun 2026
Statement geographicalus-gaap:StatementGeographicalAxis14 members · 128 facts
- US21 · Dec 2014 to Mar 2018
- Jp11 · Dec 2015 to Dec 2025
- Us11 · Dec 2015 to Dec 2025
- Other countries11 · Dec 2015 to Dec 2025
- Asia pacific11 · Dec 2015 to Dec 2025
- Emea11 · Dec 2015 to Dec 2025
- Non Us10 · Dec 2015 to Mar 2018
- Latin america9 · Dec 2015 to Dec 2025
- Asia Pacific6 · Dec 2014 to Mar 2018
- EMEA6 · Dec 2014 to Mar 2018
- JP6 · Dec 2014 to Mar 2018
- Latin America6 · Dec 2014 to Mar 2018
- Other Countries6 · Dec 2014 to Mar 2018
- VE3 · Jun 2015 to Dec 2015
Product or serviceus-gaap:ProductOrServiceAxis30 members · 91 facts
- Gardasil gardasil97 · Dec 2016 to Dec 2022
- Bridion6 · Dec 2017 to Dec 2022
- Dificid6 · Dec 2016 to Dec 2021
- Implanon nexplanon5 · Dec 2016 to Dec 2020
- Sivextro5 · Dec 2016 to Dec 2021
- Zerbaxa5 · Dec 2018 to Dec 2022
- Zontivity5 · Mar 2016 to Dec 2016
- Grastek Ragwitek4 · Jun 2016 to Dec 2016
- House Dust Mite4 · Jun 2016 to Dec 2016
- Intron A4 · Jun 2017 to Dec 2017
- Simponi4 · Dec 2017 to Dec 2021
- Next Generation Ring4 · Jun 2016 to Dec 2016
- Surotomycin4 · Jun 2015 to Dec 2015
- Uprifosbuvir4 · Dec 2016 to Dec 2017
- Adempas3 · Dec 2016 to Dec 2018
- Intron a3 · Jun 2017 to Dec 2017
- BE Tinhibitor2 · Dec 2016
- Monoclonalantibody2 · Dec 2016
- Vytorin2 · Dec 2016 to Dec 2017
- Zetia2 · Dec 2016 to Dec 2017
- Diabetestreatment1 · Dec 2016
- Gardasil1 · Dec 2016
- Nasonex1 · Dec 2016
- Nuvaring1 · Dec 2016
- Uprifosbuvir1 · Dec 2016
- Pegintron1 · Dec 2014
- Rebetol1 · Dec 2014
- Saphris1 · Dec 2014
- Verubecestat1 · Dec 2017
- Victrelis1 · Dec 2014
Product or servicesrt:ProductOrServiceAxis25 members · 68 facts
- COVID1910 · Dec 2020 to Dec 2021
- Animal health7 · Dec 2019 to Dec 2025
- Lynparza6 · Dec 2020 to Dec 2022
- Januvia Janumet5 · Dec 2023 to Mar 2025
- Verquvo5 · Mar 2021 to Dec 2021
- Uprifosbuvir4 · Dec 2016 to Dec 2017
- Zerbaxa4 · Dec 2020 to Dec 2025
- Lenvima3 · Mar 2023 to Sep 2023
- Sivextro3 · Sep 2019 to Dec 2019
- Smart Cells Program3 · Dec 2016 to Dec 2018
- Intron A2 · Dec 2017
- I Omet Pharma Ltd2 · Dec 2019
- Lyfnua2 · Dec 2024
- BE Tinhibitor1 · Dec 2016
- Gefapixant1 · Sep 2018
- Grastek Ragwitek1 · Dec 2016
- House Dust Mite1 · Dec 2016
- Monoclonalantibody1 · Dec 2016
- Sentinel1 · Jul 2020
- Sivextro1 · Sep 2019
- Nemtabrutinib1 · Dec 2021
- Next Generation Ring1 · Dec 2016
- Verubecestat1 · Dec 2017
- Vioxx1 · Dec 2020
- Zontivity1 · Dec 2016
Text from filings
Management commentary and risk factors, extracted from SEC filings only.
- Earnings-release commentary200 claims from 8 reports · Sep 2024 to Jun 2026
- Management discussion (MD&A) commentary259 claims from 8 reports · Sep 2024 to Jun 2026
- Risk-factor changes12 claims from 1 reports · Dec 2025
- Risk factors60 risks from 2 annual reports · 2024 to 2025
Earnings calls
40 calls · May 2016 to Aug 2026Transcripts with management claims and analyst questions, one per fiscal period.
- FY2026 Q2Aug 4, 2026
- FY2026 Q1Apr 30, 2026
- FY2025 Q4Feb 3, 2026
- FY2025 Q3Oct 30, 2025
- FY2025 Q2Jul 29, 2025
- FY2025 Q1Apr 24, 2025
- FY2024 Q4Feb 4, 2025
- FY2024 Q3Oct 31, 2024
- FY2024 Q2Jul 30, 2024
- FY2024 Q1Apr 25, 2024
- FY2023 Q4Feb 1, 2024
- FY2023 Q3Oct 26, 2023
- FY2023 Q2Aug 1, 2023
- FY2023 Q1Apr 27, 2023
- FY2022 Q4Feb 2, 2023
- FY2022 Q3Oct 27, 2022
Executive media
16 appearancesPodcasts, interviews and conference appearances by the company's executives, with their claims.
- TV interviews13 · Apr 2020 to Sep 2025
- Other appearances2 · Jul 2020
- Conference talks1 · Oct 2021
Reports are counted as filed reports with at least one served fact. Counts are read from the database (last read Oct 16, 2026) and refreshed every few hours.